Kukoamine A inhibits C‐C motif chemokine receptor 5 to attenuate lipopolysaccharide‐induced lung injury.
- Published in:
- Drug Development Research, 2022, v. 83, n. 6, p. 1455, doi. 10.1002/ddr.21975
- By:
- Publication type:
- Article
Works matching IS 02724391 AND DT 2022 AND VI 83 AND IP 6
Results: 21
1
2
Novel matrinic acid derivatives bearing 2‐anilinothiazole structure for non‐small cell lung cancer treatment with improved Hsp90 targeting effect.
- Published in:
- Drug Development Research, 2022, v. 83, n. 6, p. 1434, doi. 10.1002/ddr.21974
- By:
- Publication type:
- Article
3
Effect of tramadol on apoptosis and synaptogenesis in hippocampal neurons: The possible role of µ‐opioid receptor.
- Published in:
- Drug Development Research, 2022, v. 83, n. 6, p. 1425, doi. 10.1002/ddr.21973
- By:
- Publication type:
- Article
4
Higher ATM expression in lymphoblastoid cell lines from centenarian compared with younger women.
- Published in:
- Drug Development Research, 2022, v. 83, n. 6, p. 1419, doi. 10.1002/ddr.21972
- By:
- Publication type:
- Article
5
Therapeutic potential of targeting the receptor for advanced glycation end products (RAGE) by small molecule inhibitors.
- Published in:
- Drug Development Research, 2022, v. 83, n. 6, p. 1257, doi. 10.1002/ddr.21971
- By:
- Publication type:
- Article
6
Downregulation of CPT1A exerts a protective effect in dextran sulfate sodium‐induced ulcerative colitis partially by inhibiting PPARα signaling pathway.
- Published in:
- Drug Development Research, 2022, v. 83, n. 6, p. 1408, doi. 10.1002/ddr.21970
- By:
- Publication type:
- Article
7
The potential of developing a protective peptide‐based vaccines against SARS‐CoV‐2.
- Published in:
- Drug Development Research, 2022, v. 83, n. 6, p. 1251, doi. 10.1002/ddr.21969
- By:
- Publication type:
- Article
8
Design, synthesis, and biological evaluation of thienopyrimidine and thienotriazine derivatives as multitarget anti‐Alzheimer agents.
- Published in:
- Drug Development Research, 2022, v. 83, n. 6, p. 1394, doi. 10.1002/ddr.21968
- By:
- Publication type:
- Article
9
Icariside II suppresses the tumorigenesis and development of ovarian cancer by regulating miR‐144‐3p/IGF2R axis.
- Published in:
- Drug Development Research, 2022, v. 83, n. 6, p. 1383, doi. 10.1002/ddr.21967
- By:
- Publication type:
- Article
10
DPP‐4 inhibitor linagliptin ameliorates imiquimod‐induced psoriasis‐like skin alterations in type 2 diabetic mice by inhibiting the MAPK/NF‐κB inflammatory pathway.
- Published in:
- Drug Development Research, 2022, v. 83, n. 6, p. 1373, doi. 10.1002/ddr.21966
- By:
- Publication type:
- Article
11
Tetrahydropalmatine induces the polarization of M1 macrophages to M2 to relieve limb ischemia‐reperfusion‐induced lung injury via inhibiting the TLR4/NF‐κB/NLRP3 signaling pathway.
- Published in:
- Drug Development Research, 2022, v. 83, n. 6, p. 1362, doi. 10.1002/ddr.21965
- By:
- Publication type:
- Article
12
Quercetin ameliorates salivary gland apoptosis and inflammation in primary Sjögren's syndrome through regulation of the leptin/OB‐R signaling.
- Published in:
- Drug Development Research, 2022, v. 83, n. 6, p. 1351, doi. 10.1002/ddr.21964
- By:
- Publication type:
- Article
13
Carnosol alleviates sevoflurane‑induced cognitive dysfunction by mediating NF‑κB pathway in aged rats.
- Published in:
- Drug Development Research, 2022, v. 83, n. 6, p. 1342, doi. 10.1002/ddr.21963
- By:
- Publication type:
- Article
14
Novel insights on [1,2]oxazolo[5,4‐e]isoindoles on multidrug resistant acute myeloid leukemia cell line.
- Published in:
- Drug Development Research, 2022, v. 83, n. 6, p. 1331, doi. 10.1002/ddr.21962
- By:
- Publication type:
- Article
15
Papaverine, a promising therapeutic agent for the treatment of COVID‐19 patients with underlying cardiovascular diseases (CVDs).
- Published in:
- Drug Development Research, 2022, v. 83, n. 6, p. 1246, doi. 10.1002/ddr.21961
- By:
- Publication type:
- Article
16
A new exploration toward adamantane derivatives as potential anti‐MDR agents: Design, synthesis, antimicrobial, and radiosterilization activity as potential topoisomerase IV and DNA gyrase inhibitors.
- Published in:
- Drug Development Research, 2022, v. 83, n. 6, p. 1305, doi. 10.1002/ddr.21960
- By:
- Publication type:
- Article
17
Pathological role of the calcium‐sensing receptor in sepsis‐induced hypotensive shock: Therapeutic possibilities and unanswered questions.
- Published in:
- Drug Development Research, 2022, v. 83, n. 6, p. 1241, doi. 10.1002/ddr.21959
- By:
- Publication type:
- Article
18
Urea derivatives carrying a thiophenylthiazole moiety: Design, synthesis, and evaluation of antitubercular and InhA inhibitory activities.
- Published in:
- Drug Development Research, 2022, v. 83, n. 6, p. 1292, doi. 10.1002/ddr.21958
- By:
- Publication type:
- Article
19
Ombuin ameliorates diabetic nephropathy in rats by anti‐inflammation and antifibrosis involving Notch 1 and PPAR γ signaling pathways.
- Published in:
- Drug Development Research, 2022, v. 83, n. 6, p. 1270, doi. 10.1002/ddr.21956
- By:
- Publication type:
- Article
20
Issue Information.
- Published in:
- Drug Development Research, 2022, v. 83, n. 6, p. 1239, doi. 10.1002/ddr.21828
- Publication type:
- Article
21
Click chemistry‐based synthesis of new benzenesulfonamide derivatives bearing triazole ring as selective carbonic anhydrase II inhibitors.
- Published in:
- Drug Development Research, 2022, v. 83, n. 6, p. 1281, doi. 10.1002/ddr.21957
- By:
- Publication type:
- Article